<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554721</url>
  </required_header>
  <id_info>
    <org_study_id>21-13-102</org_study_id>
    <secondary_id>2013-002633-38</secondary_id>
    <nct_id>NCT02554721</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study of Cilostazol in Healthy Volunteers</brief_title>
  <acronym>CiloMecT</acronym>
  <official_title>Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the effects of Cilostazol,
      Acetylsalycylic acid and Clopidogrel alone as well as combinations of
      Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo Platelet Function (PF)
      testing.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ex-vivo inhibition of platelet aggregation from baseline</measure>
    <time_frame>Day 14(Baseline), Day 22, and Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change skin bleeding time from baseline</measure>
    <time_frame>Day 14(Baseline), Day 22, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change safety from baseline</measure>
    <time_frame>Baseline(Day0), Day7, Day 14, Day 21, and Day 28</time_frame>
    <description>Vital signs, Physical examination, ECG, Safety lab, Adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1 (CYP2C19 Wild Type)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (CYP2C19 Wild Type)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (CYP2C19 heterozygous (*1/*2) )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (CYP2C19 homozygous (*2/*2))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <arm_group_label>Group 1 (CYP2C19 Wild Type)</arm_group_label>
    <arm_group_label>Group 2 (CYP2C19 Wild Type)</arm_group_label>
    <arm_group_label>Group 3 (CYP2C19 heterozygous (*1/*2) )</arm_group_label>
    <arm_group_label>Group 4 (CYP2C19 homozygous (*2/*2))</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <arm_group_label>Group 1 (CYP2C19 Wild Type)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Group 2 (CYP2C19 Wild Type)</arm_group_label>
    <arm_group_label>Group 3 (CYP2C19 heterozygous (*1/*2) )</arm_group_label>
    <arm_group_label>Group 4 (CYP2C19 homozygous (*2/*2))</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian male subjects

          -  Able to read, to write and to fully understand German language

          -  Provision of written informed consent before screening and baseline

          -  BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg,
             inclusive

          -  Good general health as determined by the investigator by medical history, physical
             examination, vital signs, electrocardiogram, baseline and safety lab

        Exclusion Criteria:

          -  Personal or family history of bleeding disorders, or reasonable suspicion of vascular
             malformations, including aneurysms

          -  Known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6
             month) haemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled
             hypertension)

          -  Use of antibiotics within thirty (30) days prior to screening and until baseline visit

          -  Clinically significant abnormalities in medical history, physical examination, vital
             signs, electrocardiogram, baseline and safety lab

          -  Supine pulse rate &gt; 100 beats/min or &lt;50 beats/min

          -  Systolic blood pressure &lt;100 or &gt;140 mmHg

          -  Diastolic blood pressure &lt;50 or &gt;90 mmHg

          -  Concomitant use of any other medication including over-the-counter preparations
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

